Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.
OBJECTIVE
To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer.


METHODS
Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56.


RESULTS
Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups.


CONCLUSIONS
We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.
a Department of Internal Medicine , Loma Linda University Medical Center , Loma Linda , California , USA.
Brian Y
BY
Park
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Rachel N
RN
Grisham
c Department of Pharmacology , Faculty of Medicine, University of Helsinki , Helsinki , Finland.
Bjørnar
B
den Hollander
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Dharmarao
D
Thapi
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Tara
T
Berman
d Antitumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center , New York , New York , USA.
Elisa
E
de Stanchina
e Department of Epidemiology and Statistics , Memorial Sloan-Kettering Cancer Center , New York , New York , USA.
Qin
Q
Zhou
f Department of Medicine , GU Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Gopa
G
Iyer
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
Carol
C
Aghajanian
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
David R
DR
Spriggs
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression; D006801:Humans; D051379:Mice; D009570:Nitriles; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; C540278:enzalutamide
Enzalutamide; OVCAR-3; androgen receptor; epithelial ovarian cancer; xenograft